stockrow
Sunday 8 November 2026
Export SCLX’s income statement to Excel — free account
Scilex Holding Company
SCLXHealthcare Drug Manufacturers General
Scilex Holding Company’s revenue for fiscal 2025 (year ended December 2025) was $30.3 million, down 46.5% from fiscal 2024.
- Revenue
- −22.8%
- EPS
- −124.4%
- Free cash flow
- −203.8%
- Total debt
- +102.7%
Quarter to June 2026, against a year earlier
1.70
0.00
0.00%
Follow SCLX
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.54 | 3.57 | 1.09 | 1.70 | |
P/FCF ratio |
7.70 | 29.57 | 0.00 | 0.00 | |
P/Operating CF |
22.26 | (6.18) | (33.24) | (7.98) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
5.67 | 5.99 | 3.40 | 4.27 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
9.61 | 47.47 | (34.89) | (7.89) | |
EV/FCF |
9.62 | 49.59 | (33.25) | (7.57) | |
Quick Ratio |
0.04 | 0.05 | 0.03 | 0.01 | |
Current Ratio |
0.05 | 0.08 | 0.08 | 0.07 | |
Net Debt/EBITDA |
(0.24) | (2.02) | (2.74) | (3.13) | |
Debt/Assets |
16.56% | 22.81% | 27.51% | 31.87% | |
Debt/Equity |
(0.25) | (0.39) | (0.32) | (0.26) | |
Asset Turnover |
0.21 | 0.13 | 0.18 | 0.19 | |
Operating CF/Net income |
(0.03) | 0.53 | 0.03 | 0.06 | |
Capex/Depreciation |
0.00 | 0.00 | (0.74) | (0.15) | |
Interest Coverage |
(66.66) | (18.58) | — | (4.82) | |
Research and Development Expense of Revenue |
36.92% | 170.42% | 37.27% | 43.65% | |
Selling, General and Administrative Expense of Revenue |
1,788.11% | 629.23% | 360.30% | 365.87% | |
Intangible Assets out of Total Assets |
0.87 | 0.38 | 0.47 | 0.50 | |
Share Based Compensation of Revenue |
30.83% | 117.73% | 42.13% | 62.27% | |
Graham Net Nets |
(2.40) | (4.98) | (13.74) | (9.82) | |
Graham Number |
105.78 | 123.61 | 180.80 | 222.03 | |
Earnings Yield |
(203.36%) | (361.42%) | (737.89%) | (623.50%) | |
Free Cash Flow Yield |
12.98% | 3.38% | (9.41%) | (33.15%) | |
Revenue per Share |
0.91 | 0.43 | 1.25 | 1.11 | |
Operating CF per Share |
0.71 | (1.58) | (0.16) | (0.98) | |
Capex per Share |
0.00 | (0.01) | (0.42) | (0.08) | |
Free Cash Flow per Share |
0.71 | (1.60) | (0.58) | (1.06) | |
Cash per Share |
0.08 | 1.00 | 0.49 | 0.08 | |
Shareholders Equity per Share |
(15.49) | (19.19) | (36.87) | (45.05) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(15.49) | (19.19) | (36.87) | (45.05) | |
Free Cash Flow |
8.23 | (17.60) | (4.01) | (7.31) | |
Working Capital |
(342.46) | (445.29) | (459.78) | (476.01) | |
Capital Expenditures |
— | (0.13) | (2.90) | (0.58) | |
Net Current Asset Value |
(439.11) | (538.37) | (505.73) | (527.81) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.03 | 0.34 | 0.08 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
21.76 | 20.84 | 10.63 | 11.60 | |
Average Payables |
55.38 | 69.44 | 79.42 | 90.10 | |
Average Inventory |
1.74 | 3.61 | 3.77 | 3.35 | |
Average Assets |
188.15 | 228.97 | 186.31 | 168.66 | |
Average Common Equity |
(195.52) | (202.20) | (232.78) | (279.74) |
Columns are period end dates · fundamentals updated 26 Oct 2026